Date: 01-Aug-2019

Orion, Bayer prostate cancer drug gets FDA approval

The compound was approved under the FDA Priority Review designation, which is reserved for medicines that may provide significant improvements in the safety or effectiveness of the treatment for serious conditions," Orion said.